Introduction {#Sec1}
============

Introduced in the 1950s, methotrexate continues to be one of the most widely used systemic immunosuppressive agents in dermatology \[[@CR1], [@CR2]\]. Whilst awareness of important potential adverse events such as hepatotoxicity, myelosuppression, and pulmonary fibrosis are reflected in robust guidelines for dosing and monitoring of treatment \[[@CR3]\], other adverse events including cutaneous ulceration remain rarely reported and poorly characterized. Cutaneous ulceration may play a crucial role as an early clinical sign of impending systemic toxicity \[[@CR4]\]. Although rare, it is of primary importance that dermatologists remain alert to cutaneous indicators of methotrexate toxicity, are aware of risk factors that may affect drug metabolism and are confident in the management of methotrexate overdose.

We present a case of methotrexate toxicity manifesting with cutaneous ulceration and review the literature, highlighting practice points relevant to dermatology.

Methotrexate {#Sec2}
============

Uses {#Sec3}
----

Methotrexate is licensed for the treatment of severe psoriasis, psoriatic arthritis, rheumatoid arthritis, and a number of malignancies, including: childhood acute lymphoblastic leukemia, lymphoproliferative disorders, choriocarcinoma, and various solid organ tumors. In addition, methotrexate is an abortifacient used in early and ectopic pregnancy and is used off-license in a host of dermatological conditions including atopic eczema \[[@CR5], [@CR6]\] and bullous pemphigoid \[[@CR1]\], as well as non-dermatological conditions, including: Crohn's disease, systemic lupus erythematosus, and myositis.

Methotrexate can be used as monotherapy or in combination with other agents including biologic therapies \[[@CR7], [@CR8]\]. Combination therapy with methotrexate and infliximab has been reported for the treatment of SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis) \[[@CR9]\], pityriasis rubra pilaris \[[@CR10]\], recalcitrant chronic plaque psoriasis \[[@CR11]\], and erythrodermic psoriasis \[[@CR12]\]. For the treatment of chronic plaque psoriasis, combination therapy of etanercept with methotrexate led to improved disease control in a randomized, double-blinded, placebo-controlled clinical trial \[[@CR13]\] as well as in reporting by individual centers \[[@CR14]\]. Combination therapy of infliximab with methotrexate led to dose reduction of infliximab when compared with combinations of infliximab and azathioprine \[[@CR15]\], increased dosing intervals \[[@CR12]\], and appears to be well tolerated when compared with methotrexate monotherapy \[[@CR16]\].

It is postulated that the addition of methotrexate to biologic therapy may allow the maintenance of therapeutic benefit through the reduction of formation of anti-infliximab autoantibodies \[[@CR11]\]. While this has not been conclusively demonstrated in dermatology patients \[[@CR17]\], evidence in rheumatology cohorts suggests that addition of immunosuppressive drugs to biologic therapy does reduce the induction of anti-tumor necrosis factor antibodies \[[@CR17]\].

Mechanism of Action {#Sec4}
-------------------

Methotrexate may be administered orally, subcutaneously, or intramuscularly. Methotrexate is primarily bound to serum albumin and excreted unchanged in the urine \[[@CR1]\]. The drug enters cells via the reduced folate carrier \[[@CR18]\] where it is modified by the addition of up to seven glutamates (methotrexate polyglutamate; MTXPG~1--7~), catalyzed by the enzyme folylpolyglutamate synthetase \[[@CR18]\]. The MTXPGs (particularly longer chain polyglutamates, i.e., MTXPG~4--7~) are not as easily transported out of cells. They increase the intracellular half-life of the drug and act on several key enzymes, including dihydrofolate reductase and thymidylate synthase, which are involved in the pyrimidine synthesis essential for DNA replication \[[@CR18]\].

Decreased DNA synthesis in activated T cells and keratinocytes may be one of the mechanisms of action of the drug in psoriasis vulgaris. However, methotrexate affects other pathways, including the synthesis of adenosine via inhibition of the enzyme 5-aminoimidazole-4-carboxamide ribonucleotide transformylase. This leads to a net increase in the release of adenosine which acts as an anti-inflammatory mediator \[[@CR19]\].

There is considerable inter-individual variation in toxicity and response to methotrexate therapy. To date, one of the largest and most comprehensive pharmacogenetic studies in psoriasis evaluated the role of single nucleotide polymorphisms (SNPs) on treatment response to methotrexate \[[@CR20]\], demonstrating SNPs in the genes encoding efflux transporter proteins are associated with response to methotrexate. Evaluation of a smaller cohort of patients demonstrated a folate carrier allele to be associated with methotrexate toxicity \[[@CR21]\]. In rheumatoid arthritis, the role of SNPs in genes coding for intracellular polyglutamates has been evaluated \[[@CR22]\] and have been found to be associated with efficacy of treatment while detectable red blood cell levels of MTXPG~4-7~ have been shown to predict clinical response \[[@CR23], [@CR24]\]. Pharmacogenomics may yet play a greater role in the prediction of efficacy and toxicity of methotrexate, with identification of genetic markers for pre-treatment testing \[[@CR25]\]. However, at present markers have only been applied in small cohorts with limited reproducibility in daily practice \[[@CR26]\].

Toxicity of Methotrexate {#Sec5}
------------------------

In dermatology, typical starting doses of oral methotrexate range from 5 to 15 mg weekly, escalating every 2--4 weeks to a maximum of around 25 mg weekly \[[@CR27]\]. Risk of toxicity with low-dose methotrexate treatment is felt to be low with no evidence of increased carcinogenicity within the dermatology population \[[@CR28]\]. Providing monitoring remains satisfactory, there is no defined maximum duration of treatment with many patients remaining on the drug for long periods of 10--15 years \[[@CR27]\].

Concomitant folic acid supplementation alongside methotrexate has been shown to reduce the incidence of gastrointestinal side effects, liver dysfunction, and improve continuance of treatment \[[@CR29]\]. Higher supplementation regimens have been posited to reduce the efficacy of methotrexate \[[@CR30], [@CR31]\], but a minimum dose of 5 mg weekly (given on any day except that of methotrexate dosing) is recommended \[[@CR3]\].

Robust guidelines exist for the screening and monitoring of patients on methotrexate for dermatological and rheumatological indications \[[@CR3], [@CR32]\]. Well-recognized side effects include: nausea/vomiting, folic acid deficiency, myelosuppression, hepatotoxicity (both as an acute transaminitis and as chronic fibrosis/cirrhosis), and pulmonary toxicity. Of these, bone marrow toxicity can occur after long-term treatment, but also at low doses at the initiation of therapy. A first dose of no more than 5 mg with repeat full blood count prior to the second dose is recommended in treatment naïve patients \[[@CR3], [@CR32]\].

Risk of hepatotoxicity is increased by concurrent alcohol consumption, obesity, hepatitis, diabetes mellitus, and cumulative doses of more than 3 g of methotrexate \[[@CR32]\]. Monitoring for liver toxicity may include regular serum liver function testing, serial measurement of procollagen III peptide, liver biopsy, and/or transient elastography scanning \[[@CR33]\], although robust evidence to support the utility of one or more potential biomarkers of liver toxicity is lacking.

A key cause of toxicity is concurrent treatment with interacting agents that decrease protein binding or reduce renal clearance. Some interactions (e.g., for proton-pump inhibitors) have been reported mainly during high-dose methotrexate regimens \[[@CR34]\] while others \[such as trimethoprim, non-steroidal anti-inflammatory drugs (NSAIDs), and salicylates\] have also been reported in patients on low-dose methotrexate \[[@CR35]\]. Patients and physicians should be alert to possible interactions and regularly review additional medication use.

A number of cutaneous adverse events have also been described, including: mucositis \[[@CR36]\], erythema multiforme \[[@CR37]\], Stevens--Johnson syndrome \[[@CR38]\], toxic epidermal necrolysis \[[@CR39], [@CR40]\], photosensitivity \[[@CR41]\], 'recall reactions' of previous photodermatoses \[[@CR42]\], exfoliative dermatitis \[[@CR43], [@CR44]\], and ulceration/skin necrosis \[[@CR4]\]. Of these, mucositis and photosensitivity are usually dose-related and more commonly associated with high-dose regimens used in chemotherapy than in low-dose therapy used in dermatology \[[@CR36], [@CR42]\].

Erythema multiforme, Stevens--Johnson syndrome, and toxic epidermal necrolysis are idiosyncratic immune reactions where the full mechanism is not yet understood. Drug interactions and genetic predisposition are felt to influence the risk of development of severe adverse drug reactions, but are not present in all cases \[[@CR45]\].

Case Report {#Sec6}
===========

We report an 83-year-old female with long-standing severe chronic plaque psoriasis who requested urgent assessment with a 3-week history of oral ulceration and a 2-week history of a flare of her psoriasis.

She had been established on methotrexate therapy for more than 10 years. During the course of the therapy, her dose had gradually escalated to 25 mg once weekly. Folic acid (5 mg) was taken once weekly on a separate day. Her cumulative dose of methotrexate was more than 7 g.

The patient suffered comorbidities, including hypertension and congestive cardiac failure. Prior to this presentation, she required hospitalization for the treatment of cardiac failure. Treatment comprised an increase in the dose of her furosemide. Her other medications were isosorbide mononitrate, lisinopril, Adcal-D~3~, and quinine sulfate. No new medications were instituted.

On attendance the patient was systemically well and afebrile. Clinically she had oral erosions to the buccal mucosa (Fig. [1](#Fig1){ref-type="fig"}) and large, painful, inflamed, and ulcerated psoriatic plaques each with a prominent tender erythematous weepy inflamed edge (Fig. [2](#Fig2){ref-type="fig"}).Fig. 1Oral erosionsFig. 2Large painful ulcerated plaques of psoriasis

Routine bloods demonstrated a low platelet count of 109 (normal range 150--400 × 10^9^/L). Renal function was normal and methotrexate level measured at the time of admission was undetectable.

Skin biopsy taken from the edge of an inflamed plaque on the trunk demonstrated attenuation of relatively atrophic epidermis with overlying parakeratotic scale and apoptotic keratinocytes (Figs. [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}).Fig. 3Histology from skin biopsy taken from the edge of an inflamed plaque on the trunkFig. 4Histology from skin biopsy taken from the edge of an inflamed plaque on the trunk

A diagnosis of methotrexate toxicity was made; the drug was discontinued and topical therapy commenced. Symptoms and signs resolved within 2 weeks following withdrawal of methotrexate. Treatment was reintroduced at a lower dose of 10 mg of methotrexate weekly with concomitant folic acid supplementation (5 mg daily for 6 days of the week, omitted on day of methotrexate dose) with no adverse effects.

Informed consent was obtained from the patient for being included in the study and for publication of the images.

Discussion {#Sec7}
==========

Methotrexate-Induced Cutaneous Ulceration {#Sec8}
-----------------------------------------

Ulceration of the skin was well-recognized with aminopterin \[[@CR46]\], the precursor to methotrexate, and was also reported shortly after the introduction of the methotrexate as a treatment for psoriasis \[[@CR47]\]. It has been at the onset of treatment \[[@CR48]\], during long-term methotrexate therapy \[[@CR49]\], and as a presenting feature of accidental overdose \[[@CR50]\].

The exact incidence of methotrexate-induced skin ulceration is difficult to assess, but appears to be rare. Roenigk et al. \[[@CR47]\] noted ulceration in 6 of 204 patients treated with methotrexate, while Lawrence and Dahl \[[@CR4]\] reported seven patients who had presented over the preceding 17-year period, but do not indicate what proportion of cases this represented.

In 1996, a literature review by Pearce and Wilson \[[@CR51]\] identified 47 cases of methotrexate-induced skin ulceration reported between 1951 and 1967, and a further 17 cases (including two of their own patients and those by Roenigk et al. \[[@CR47]\] and Lawrence and Dahl \[[@CR4]\]) between 1967 and 1996. A PubMed search using the terms "methotrexate" AND "ulceration" identified a further 18 cases published after 1996 (Table [1](#Tab1){ref-type="table"}) \[[@CR48]--[@CR50], [@CR52]--[@CR61]\].Table 1Methotrexate-induced cutaneous ulceration: case reports since 1996Year of publicationAuthorsReferencesGenderAge of patient (years)DiagnosisDose of methotrexateIntended dose?Suspected drug interactionOther risk factorsLeucovorin given?1998Ben-Amitai et al.\[[@CR52]\]Male67Rheumatoid arthritis5 mg dailyNoNoNoNo2000Montero et al.\[[@CR56]\]Male52Rheumatoid arthritis15 mg weeklyYesNoDiabetes mellitus, obesity, chronic kidney diseaseNo2001Del Pozo et al.\[[@CR53]\]Female39Rheumatoid arthritis15 mg weeklyYesYes (indomethacin)NoNo2003Kazlow et al.\[[@CR54]\]Male58Chronic plaque psoriasis15 mg weeklyYesNoNoNo2008Agarwal et al. (case 1)\[[@CR50]\]Male57Chronic plaque psoriasis37.5 mg (7.5 mg daily for 5 days)NoNoNoYes (25 mg QDS day 1, 10 mg QDS days 2--3 with blood transfusion)2008Agarwal et al. (case 2)\[[@CR50]\]Male68Chronic plaque psoriasis105 mg (15 mg daily for 7 days)NoNoNoNo2008Bookstaver et al.\[[@CR55]\]Female59Chronic plaque psoriasis2.5 mg daily (\~360 mg total)NoYes (ibuprofen)Diabetes mellitus, obesity, ischaemic heart diseaseYes (duration not stated)2008Breneman et al. (case 1)\[[@CR60]\]Male81Mycosis fungoides10 mg weeklyYesNoNone statedNo2008Brenerman et al. (case 2)\[[@CR60]\]Male78Mycosis fungoides40 mg weekly (IV)YesFurosemideNone statedNo2008Brenerman et al. (case 3)\[[@CR60]\]Female77Mycosis fungoides40 mg weeklyYesNoNone statedNo2008Brenerman et al. (case 4)\[[@CR60]\]Male67Mycosis fungoides60 mg weekly (IV)YesNoAcute renal failureYes (dose not stated)2008Hocaoglu et al.\[[@CR48]\]Male64Rheumatoid arthritis15 mg (5 mg for 3 days)NoNoNoYes2008Warner et al.\[[@CR57]\]Female36Chronic plaque psoriasis and psoriatic arthritis12.5 mg weeklyYesNoNoNo2009Bilaç et al.\[[@CR58]\]Male62Chronic plaque psoriasis and psoriatic arthritis25 mg weeklyYesNoNoNot stated2011Fridlington et al.\[[@CR61]\]Male37Chronic plaque psoriasisUnknown IV doseNoYes (trimethoprim/sulfamethoxasole)NoNo2011Kurian et al.\[[@CR59]\]Male67Rheumatoid arthritis25 mg weekly (S/C)YesNoNoNo2012Wong et al. (case 1)\[[@CR49]\]Male52Chronic plaque psoriasis and psoriatic arthritis3.75 mg dailyNoNoDiabetes mellitus, chronic kidney disease, hepatitis BYes (25 mg QDS for 14 days with G-CSF)2012Wong et al. (case 2)\[[@CR49]\]Female50Chronic plaque psoriasis15 mg weeklyYesNoDiabetes mellitusNo*G-CSF* granulocyte colony-stimulating factor, *IV* intravenous, *S/C* subcutaneous, *QDS* four times daily

Perhaps surprisingly, most cases of methotrexate-induced ulceration have been reported in patients with psoriasis on low-dose treatment rather than in those on high-dose oncology regimens. It is postulated that that the increased proliferation of keratinocytes within psoriatic plaques makes them particularly vulnerable to the effects of folate-antagonism. However, Lawrence and Dahl \[[@CR4]\] described two patterns of methotrexate-induced ulceration: type 1 as superficial ulceration of existing psoriatic plaques and type 2 as ulceration of non-psoriatic skin. Isolated cases of methotrexate-induced ulceration in patients without a history of psoriasis have been reported including patients on low-dose treatment for rheumatoid arthritis \[[@CR52], [@CR56]\] and patients undergoing treatment for mycosis fungoides \[[@CR60]\].

Patients may present with isolated cutaneous lesions or with other signs of methotrexate toxicity including mucositis, liver dysfunction, and/or myelosuppression. Psoriatic plaques and/or normal skin becomes painful, erythematous, and superficially eroded. Early cutaneous ulceration may be mistaken for a flare of psoriasis leading to erroneous increase in methotrexate use by either patient \[[@CR50]\] or physician \[[@CR4]\].

Diagnostic biopsy is rarely required, however, histological features of methotrexate-induced ulceration include swollen keratinocytes with diminished nuclear and cytoplasmic staining and occasional vacuolated or dyskeratotic cells indicative of incipient epidermal necrosis \[[@CR4]\]. Dermal changes include vascular dilatation and lymphocytic infiltrates \[[@CR4], [@CR58]\]. Non-specific ulceration may also be present \[[@CR58]\].

As with other methotrexate toxicity, skin ulceration has been described in the context of an adverse drug interaction when new medications are added to an existing methotrexate regimen \[[@CR62]\]. Examples include; trimethoprim, amiodarone \[[@CR63]\], furosemide \[[@CR63]\], penicillin \[[@CR63]\], and NSAIDs \[[@CR51]\]. Additional risk factors include renal impairment and diabetes mellitus \[[@CR50]\].

Treatment of Methotrexate Toxicity {#Sec9}
----------------------------------

Folate supplementation during treatment has been shown to reduce methotrexate toxicity \[[@CR31]\] and improve compliance with treatment. There is considerable variation in the prescription of folic acid, however, a minimum of 5 mg weekly (to be taken the day after methotrexate therapy) is recommended for UK practice \[[@CR3]\].

In cases of ulceration, withdrawal of methotrexate supported by skin-directed therapy usually leads to rapid improvement in ulceration with many patients showing signs of healing within a few days; however, in isolated cases ulceration persists for years \[[@CR4]\].

Folinic acid (calcium leucovorin) is used for treatment of methotrexate overdose including ulceration \[[@CR50], [@CR55]\]. This treatment should be administered as soon as possible after exposure to methotrexate in 20 mg doses (or 10 mg/m^2^) intravenously or intramuscularly, every 6 h until serum methotrexate concentration falls below 10^−8^ M (assessed every 12--24 h) or until the total dose of folinic acid is at least equal to the dose of methotrexate \[[@CR32]\].

In patients with impaired renal function receiving high-dose methotrexate for cancer therapy who develop toxicity, glucarpidase has been used to hydrolyze methotrexate aiding clearance \[[@CR64]\]. Glucarpidase is a recombinant bacterial enzyme and received Food and Drug Administration approval in 2012 \[[@CR65]\]. It also has some limited application in cases of intrathecal methotrexate toxicity \[[@CR65]\]. As yet there are no reports of this agent used within the dermatology population, however, there might be applications in cases of acute overdose.

Conclusion {#Sec10}
==========

Our case presented with typical manifestations of methotrexate-induced ulceration on a background of considerable, but previously well-tolerated, methotrexate use. Early recognition of cutaneous findings as a marker of methotrexate toxicity in the reported case allowed prompt cessation of the drug avoiding serious morbidity.

Methotrexate is a well-established element of the dermatology therapeutic arsenal governed by robust guidelines \[[@CR32]\] for introduction and monitoring which aim to minimize patient risk. Pharmacogenomic evaluation of methotrexate may allow for future pre-treatment testing for risk of efficacy and toxicity. It is vital that dermatologists are confident in the recognition and management cutaneous and non-cutaneous manifestations of methotrexate toxicity in their own patients and those of other specialties.
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